Multicenter Retrospective Study of Isoflurane in Refractory and Super-Refractory Status Epilepticus

Not yet recruiting

• Conditions: Refractory Status Epilepticus
• Interventions: Drug: Isoflurane

• Registration Number: NCT05830864
• Lead Sponsor: Hopital of Melun

Brief Summary

Isoflurane might be used as anticonvulsive therapy in refractory status epilepticus. The aim of the study is to assess the efficiency of Isoflurane in this indication.

Detailed Description

Investigators will collect in 4 ICUs the data from consecutive patients hospitalized between january 2016 and january 2023. Included patient were those treated by Isoflurane for refractory status epilepticus.

Study Timeline

• Study First Submitted: 2023-03-31
• Study First Submitted QC: 2023-04-13
• Study First Posted: 2023-04-26
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-22
• Last Update Posted: 2024-02-23
• Study Start: 2024-03-01
• Primary Completion: 2024-09-01
• Study Completion: 2024-12-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Age > 18 years, hospitalized in ICU between 2016-01-01 and 2023-01-01, suffering refractory status epilepticus treated by inhaled Isoflurane as third anticonvulsive therapy

Exclusion Criteria

• post-anoxic refractory status epilepticus after cardiac arrest, withdrawal of consent for medical data use

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Main cohort	Isoflurane	Adult patients with refractory status epilepticus treated by Isoflurane as third anticonvulsive therapy

Primary Outcome Measures

Name	Time	Method
rate of crisis control	3 months	rate of patients with crisis control or complete awakening

Trial Locations

Locations (4)

Ch Bethune Beuvry; 🇫🇷 Beuvry, France

CHU Brest; 🇫🇷 Brest, France

GH Sud Ile de France, Hôpital de Melun-Sénart; 🇫🇷 Melun, France

CH Toulon - Sainte Musse; 🇫🇷 Toulon, France